Published in Curr Opin Rheumatol on November 01, 1997
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med (2002) 1.78
Death, autoantigen modifications, and tolerance. Arthritis Res (2000) 1.75
Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases. Am J Pathol (2003) 1.02
Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol (2006) 0.96
Macrophage plasticity in skeletal muscle repair. Biomed Res Int (2014) 0.95
B cells in autoimmunity. Proc Natl Acad Sci U S A (2000) 0.92
Demographic and clinical features of inclusion body myositis in North America. Muscle Nerve (2015) 0.92
Disease-associated increased HIF-1, alphavbeta3 integrin, and Flt-1 do not suffice to compensate the damage-inducing loss of blood vessels in inflammatory myopathies. Rheumatol Int (2003) 0.90
Plasma cell-like morphology of Th1-cytokine-producing cells associated with the loss of CD3 expression. Am J Pathol (2004) 0.88
MR imaging findings of focal myositis: a pseudotumour that may mimic muscle neoplasm. Skeletal Radiol (2009) 0.88
Dermatomyositis associated with lymphoproliferative disorder of NK cells and occult small cell lung carcinoma. Clin Rheumatol (2004) 0.80
Distinct inflammatory properties of late-activated macrophages in inflammatory myopathies. Acta Myol (2008) 0.80
Vitamin D receptor agonists: suitable candidates as novel therapeutic options in autoimmune inflammatory myopathy. Biomed Res Int (2014) 0.80
RP105-negative B cells in systemic lupus erythematosus. Clin Dev Immunol (2011) 0.79
New autoantibody detection technologies yield novel insights into autoimmune disease. Curr Opin Rheumatol (2014) 0.79
The vitamin D receptor agonist BXL-01-0029 as a potential new pharmacological tool for the treatment of inflammatory myopathies. PLoS One (2013) 0.78
From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies. Clin Exp Immunol (2001) 0.75
Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med (2000) 3.84
Duchenne dystrophy: electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber. Neurology (1975) 2.89
Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med (1999) 2.84
Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol (1984) 2.66
Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron (1995) 2.55
Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol (1990) 2.42
Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science (1973) 2.34
Fingerprint body myopathy, a newly recognized congenital muscle disease. Mayo Clin Proc (1972) 2.34
Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor epsilon subunit. Neuron (1996) 2.27
Mutation in the M1 domain of the acetylcholine receptor alpha subunit decreases the rate of agonist dissociation. J Gen Physiol (1997) 2.25
Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell (1994) 2.15
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology (2008) 2.07
The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and aspects of pathophysiology. Ann Intern Med (1990) 2.06
Polymyositis mediated by T lymphocytes that express the gamma/delta receptor. N Engl J Med (1991) 2.00
Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit. Proc Natl Acad Sci U S A (1995) 1.92
Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci U S A (2001) 1.90
Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol (1989) 1.89
Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc Natl Acad Sci U S A (1998) 1.85
Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc (1977) 1.85
The immunobiology of muscle. Immunol Today (1994) 1.83
Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A (1989) 1.82
Inclusion body myositis. Observations in 40 patients. Brain (1989) 1.82
Acetylcholinesterase of human erythrocytes and neuromuscular junctions: homologies revealed by monoclonal antibodies. Proc Natl Acad Sci U S A (1982) 1.79
Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology (1977) 1.78
AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology (2000) 1.77
Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology (2011) 1.77
Myasthenia gravis and myasthenic syndromes. Ann Neurol (1984) 1.77
Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies. Brain (1970) 1.72
The spectrum and diagnosis of acid maltase deficiency. Neurology (1973) 1.71
Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A (1983) 1.71
Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain (1997) 1.69
Serum choline activates mutant acetylcholine receptors that cause slow channel congenital myasthenic syndromes. Proc Natl Acad Sci U S A (1999) 1.68
Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567,000 muscle fibers in 114 biopsies. Neurology (1978) 1.63
Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome. Ann N Y Acad Sci (1971) 1.62
Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor alpha subunit. J Neurosci (1997) 1.59
Multicore disease. A recently recognized congenital myopathy associated with multifocal degeneration of muscle fibers. Mayo Clin Proc (1971) 1.56
Failure of inactivation of Duchenne dystrophy X-chromosome in one of female identical twins. Neurology (1977) 1.53
Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies. J Exp Med (1976) 1.53
A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol (1982) 1.52
Congenital myasthenic syndrome caused by a mutation in the Ets-binding site of the promoter region of the acetylcholine receptor epsilon subunit gene. Neuromuscul Disord (1999) 1.52
Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation. Hum Mol Genet (1994) 1.49
Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor epsilon subunit gene: identification and functional characterization of six new mutations. Hum Mol Genet (1997) 1.45
Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology (1991) 1.45
Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol (1984) 1.43
Acetylcholine receptor M3 domain: stereochemical and volume contributions to channel gating. Nat Neurosci (1999) 1.42
Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol (1995) 1.42
The syndrome of systemic carnitine deficiency. Clinical, morphologic, biochemical, and pathophysiologic features. Neurology (1975) 1.38
A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release. Ann Neurol (1977) 1.36
Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol (1980) 1.35
Autophagic glycogenosis of late onset with mitochondrial abnormalities: light and electron microscopic observations. Mayo Clin Proc (1968) 1.33
Carnitine metabolism and inborn errors. J Inherit Metab Dis (1984) 1.30
The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann N Y Acad Sci (1976) 1.30
Experimental chloroquine myopathy. J Neuropathol Exp Neurol (1970) 1.30
Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med (1980) 1.29
Interferon gamma gene expression in sensory neurons: evidence for autocrine gene regulation. J Exp Med (1997) 1.29
The earliest pathologic alterations in dysferlinopathy. Neurology (2001) 1.28
Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest (1993) 1.27
Myofibrillar myopathy with abnormal foci of desmin positivity. I. Light and electron microscopy analysis of 10 cases. J Neuropathol Exp Neurol (1996) 1.27
Late-onset rod myopathy (a new syndrome?): light and electron microscopic observations in two cases. Mayo Clin Proc (1966) 1.25
Coexistence in human and primate neuromuscular junctions of enzymes synthesizing acetylcholine, catecholamine, taurine, and gamma-aminobutyric acid. Proc Natl Acad Sci U S A (1982) 1.25
Amyloid myopathy: an underdiagnosed entity. Ann Neurol (1998) 1.25
Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Ann Neurol (1982) 1.25
Histometric study of neuromuscular junction ultrastructure. I. Myasthenia gravis. Neurology (1972) 1.24
Retinocochleocerebral vasculopathy. Medicine (Baltimore) (1998) 1.23
Myofibrillar myopathy with abnormal foci of desmin positivity. II. Immunocytochemical analysis reveals accumulation of multiple other proteins. J Neuropathol Exp Neurol (1996) 1.22
Trophic functions of the neuron. II. Denervation and regulation of muscle. Morphological effects of denervation of muscle. A quantitative ultrastructural study. Ann N Y Acad Sci (1974) 1.22
Duchenne dystrophy. II. Morphometric study of motor end-plate fine structure. Brain (1974) 1.22
Motor end-plate fine structure in acrylamide dying-back neuropathy: a sequential morphometric study. Neurology (1974) 1.21
Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg (1997) 1.19
Fundamental gating mechanism of nicotinic receptor channel revealed by mutation causing a congenital myasthenic syndrome. J Gen Physiol (2000) 1.18
Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology (2005) 1.18
Mode switching kinetics produced by a naturally occurring mutation in the cytoplasmic loop of the human acetylcholine receptor epsilon subunit. Neuron (1998) 1.17
Congenital endplate acetylcholinesterase deficiency. Brain (1993) 1.16
Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol (1986) 1.16
Electron microscopic observations in thyrotoxic and corticosteroid-induced myopathies. Mayo Clin Proc (1966) 1.15
Hypoglycemia, hepatic dysfunction, muscle weakness, cardiomyopathy, free carnitine deficiency and long-chain acylcarnitine excess responsive to medium chain triglyceride diet. Pediatr Res (1983) 1.13
Carnitine metabolism and deficiency syndromes. Mayo Clin Proc (1983) 1.12
Regulatory properties of a mutant carnitine palmitoyltransferase in human skeletal muscle. Eur J Biochem (1985) 1.11
Acid maltase deficiency in adults presenting as respiratory failure. Am J Med (1978) 1.11
Observations on organization of Z-disk components and on rod-bodies of Z-disk origin. J Cell Biol (1971) 1.11
Normal and denervated muscle. A morphometric study of fine structure. Neurology (1973) 1.10
Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure. Neurology (1973) 1.10
Tissue distribution of carnitine biosynthetic enzymes in man. Biochim Biophys Acta (1980) 1.10
Monoclonal antibody analysis of mononuclear cells in myopathies. IV: Cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol (1988) 1.10
Evolution and content of vacuoles in primary hypokalemic periodic paralysis. Mayo Clin Proc (1971) 1.09
Fatal systemic carnitine deficiency with lipid storage in skeletal muscle, heart, liver and kidney. J Neurol Sci (1976) 1.09
Neuromuscular manifestations of Graves' disease. Mayo Clin Proc (1972) 1.09
Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J Neurol Sci (1989) 1.09
Congenital end-plate acetylcholinesterase deficiency caused by a nonsense mutation and an A-->G splice-donor-site mutation at position +3 of the collagenlike-tail-subunit gene (COLQ): how does G at position +3 result in aberrant splicing? Am J Hum Genet (1999) 1.08
Lipid storage myopathy responsive to prednisone. Arch Neurol (1972) 1.08
Induction of HLA-DR expression on human myoblasts with interferon-gamma. Am J Pathol (1990) 1.08
Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol (1978) 1.08
Nemaline (Z disk) myopathy: observations on the origin, structure, and solubility properties of the nemaline structures. J Neuropathol Exp Neurol (1967) 1.07
The spectrum of mutations causing end-plate acetylcholinesterase deficiency. Ann Neurol (2000) 1.07
Myofibrillar myopathy. Ann Neurol (1999) 1.07
Unexpected sarcolemmal complement membrane attack complex deposits on nonnecrotic muscle fibers in muscular dystrophies. Neurology (1998) 1.06
The cytoplasmic body: another structural anomaly of the Z disk. Acta Neuropathol (1969) 1.05
Muscle blood flow in Duchenne type muscular dystrophy, limb-girdle dystrophy, polymyositis, and in normal controls. J Neurol Neurosurg Psychiatry (1974) 1.05
Congenital myasthenic syndromes: II. Syndrome attributed to abnormal interaction of acetylcholine with its receptor. Muscle Nerve (1993) 1.05